NASDAQ:XON - Intrexon Stock Price, Forecast & News

Intrexon trades on the NASDAQ under the ticker symbol "XON."

Intrexon Corp (NASDAQ:XON) announced its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.05. The biotechnology company earned $35.99 million during the quarter, compared to analysts' expectations of $29.62 million. Intrexon had a negative net margin of 393.13% and a negative return on equity of 45.51%. The firm's revenue for the quarter was down 20.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.51) EPS. View Intrexon's Earnings History.

Intrexon is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Intrexon.

3 equities research analysts have issued 1 year target prices for Intrexon's shares. Their forecasts range from $6.00 to $43.00. On average, they anticipate Intrexon's share price to reach $19.67 in the next year. This suggests a possible upside of 344.9% from the stock's current price. View Analyst Price Targets for Intrexon.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intrexon in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intrexon.

Media stories about XON stock have been trending neutral this week, InfoTrie reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Intrexon earned a coverage optimism score of 0.5 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Intrexon.

Some companies that are related to Intrexon include National Research (NRC), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Auxly Cannabis Group (CBWTF), Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX), Geovax Labs (GOVX), Bioanalytical Systems (BASI), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Cleveland BioLabs (CBLI), Tenax Therapeutics (TENX) and US Stem Cell (USRM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Intrexon investors own include Nordic American Tanker (NAT), ZIOPHARM Oncology (ZIOP), Hess (HES), Boeing (BA), Opko Health (OPK), Celldex Therapeutics (CLDX), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Alibaba Group (BABA) and General Electric (GE).

Intrexon's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Third Security LLC (46.42%), State Street Corp (2.27%), Nikko Asset Management Americas Inc. (1.92%), Sumitomo Mitsui Trust Holdings Inc. (1.92%), Jacobs Levy Equity Management Inc. (0.67%) and First Eagle Investment Management LLC (0.50%). Company insiders that own Intrexon stock include Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk, Rick L Sterling, Robert F Walsh III, Thomas Bostick and Thomas D Reed. View Institutional Ownership Trends for Intrexon.

XON stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Wellington Shields Capital Management LLC, Rafferty Asset Management LLC, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Cubist Systematic Strategies LLC, Goldman Sachs Group Inc. and Bank of America Corp DE. Company insiders that have sold Intrexon company stock in the last year include Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Randal J Kirk, Rick L Sterling, Robert F Walsh III, Thomas Bostick and Thomas D Reed. View Insider Buying and Selling for Intrexon.

XON stock was acquired by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Third Security LLC, AXA, ARK Investment Management LLC, Iridian Asset Management LLC CT, Alpine Global Management LLC, California Public Employees Retirement System and Russell Investments Group Ltd.. View Insider Buying and Selling for Intrexon.

Shares of XON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XON stock can currently be purchased for approximately $4.42.

Intrexon has a market capitalization of $719.06 million and generates $160.57 million in revenue each year. The biotechnology company earns $-509,340,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. View Additional Information About Intrexon.

The official website for Intrexon is http://www.dna.com/.

Intrexon's mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company can be reached via phone at 301-556-9900 or via email at [email protected]